



Weill Cornell Medical College



14th Annual Controversies in the Management of the HIV-Infected Patient

**Friday, November 11, 2011
1:00 P.M. – 5:00 P.M.**

**Weill Cornell Medical College
Uris Auditorium
1300 York Avenue (at 69th Street)
New York, NY**

Marshall J. Glesby, M.D., Ph.D., Course Director

Associate Professor of Medicine and Public Health
Director, Cornell Clinical Trials Unit
Weill Cornell Medical College

Roy M. Gulick, M.D., M.P.H., Course Co-Director

Professor of Medicine
Chief, Division of Infectious Diseases
Weill Cornell Medical College

Planning Committee Members:

Marshall J. Glesby, M.D., Ph.D.

Associate Professor of Medicine and Public Health
Director, Cornell Clinical Trials Unit
Weill Cornell Medical College

Roy M. Gulick, M.D., M.P.H.

Professor of Medicine
Chief, Division of Infectious Diseases
Weill Cornell Medical College

Timothy J. Wilkin, M.D., M.P.H.

Associate Professor of Medicine
Weill Cornell Medical College

Kristen Marks, M.D., M.P.H.

Assistant Professor of Medicine
Weill Cornell Medical College

Unrestricted educational grants have been applied for. Sponsorship information will be announced on the day of the event.

Agenda

1:00 p.m. – 1:15 p.m.

Welcome and Opening Comments

Marshall J. Glesby, M.D., Ph.D.
Associate Professor of Medicine and Public Health
Weill Cornell Medical College

1:15 p.m. – 1:45 p.m.

HIV Infection in the U.S. Today: Communities Impacted by an Epidemic of Hotspots

Sally Hodder, M.D.
Professor of Medicine
University of Medicine & Dentistry of New Jersey

1:45 p.m. – 2:15 p.m.

Controversies in HIV Therapy and Prevention

Roy M. Gulick, M.D., M.P.H.
Professor of Medicine
Weill Cornell Medical College

2:15 p.m. – 2:45 p.m.

Inflammation and HIV: A Double-Edge Sword?

Marshall J. Glesby, M.D., Ph.D.
Associate Professor of Medicine and Public Health
Weill Cornell Medical College

2:45 p.m. – 3:00 p.m. Questions & Answers

3:00 p.m. – 3:30 p.m. Coffee Break

3:30 p.m. – 4:00 p.m.

HCV/HIV Co-Infection

Andrew Talal, M.D., M.P.H.
Associate Professor of Medicine
Weill Cornell Medical College

4:00 p.m. – 4:30 p.m.

Drug-Drug Interactions with Direct Acting Antivirals for HCV

John Faragon, Pharm.D.
Regional Pharmacy Director – NY/NJ AIDS Education and Training Center
Pharmacist – Albany Medical Center

4:30 p.m. – 4:45 p.m. Questions & Answers

4:45 p.m. – 5:00 p.m. Closing Remarks

TARGET AUDIENCE: Physicians, Physician Assistants, Nurse Practitioners, Nurses, Pharmacists and other clinicians who may encounter HIV-infected patients in practice.

IDENTIFIED PRACTICE GAPS/EDUCATIONAL NEEDS: HIV treatment guidelines have been evolving over the past year such that earlier initiation of therapy is now recommended despite some controversy. Inflammation and immune activation are newly recognized concerns that may be driving co-morbidities in HIV-infected patients. Co-infection with HCV is common in persons with HIV and is an important clinical problem. There are newly available HCV protease inhibitors with proven efficacy in HCV mono-infection; their use in HIV-infected patients will be complicated by drug-drug interactions with antiretrovirals. Despite the availability of effective therapies for HIV and its complications, there remain major disparities among segments of the U.S. population with respect to access to care. The speakers will address these areas of controversy and gaps in the average clinician's knowledge base.

COURSE DESCRIPTION: This half-day course consists of five lectures by leading experts from the fields of infectious diseases, hepatology, and pharmacology. There will be ample time for audience participation and opportunities to engage the speakers in dialogue about current controversies in HIV management.

COURSE OBJECTIVES: This Weill Cornell CME activity is designed to lead to improved patient care. The Controversies in the Management of the HIV Infected Patient program will strive to:

1. Recognize communities impacted by the current US HIV epidemic and possible effective strategies of HIV Prevention in those communities.
2. Consider new approaches to HIV treatment and HIV prevention.
3. Factor the potential contributions of inflammation and immune activation to end organ diseases in the HIV-infected patient.
4. Utilize recent data on the safety and efficacy of HCV protease inhibitors.
5. Identify potential concerns about drug-drug interactions between direct acting HCV drugs and antiretrovirals.

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS:

Weill Cornell Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Weill Cornell Medical College designates this live activity for a maximum of 3.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EVALUATION: The CME Evaluation Form is included in your syllabus. Completed forms will be collected at the door at the end of this activity. We encourage you to complete the Evaluation Form as this will allow us to assess the degree to which the activity met its objectives. It will also guide the planning of future activities and inform decisions about improving the educational program.

REGISTRATION: [CLICK HERE](#) to register on line or call either 212-746-4177 or 212-746-7204. The fee for this course is \$60 before November 8th, \$75 afterwards. Free for residents, fellows and medical students.

WCMC is accessible for individuals with disabilities or special needs. Participants with special needs are requested to contact the Office of CME at 212-746-2631.